Nestlé May Shed Peanut Allergy Treatment as Sales Disappoint
The world’s only approved peanut allergy drug has so far proved a flop.
Nestlé SA said Tuesday it would explore strategic options for the treatment, effectively putting the drug up for sale, following lower-than-expected demand from doctors and patients. The move comes just two years after the packaged-food giant agreed to buy the developer of the drug, called Palforzia, in a $2.6 billion deal.
“We did have high hopes for this business,” Nestlé Chief Executive…